U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H33ClO6
Molecular Weight 464.979
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BECLOMETHASONE 17-MONOPROPIONATE

SMILES

[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(Cl)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=OHYGPBKGZGRQKT-XGQKBEPLSA-N
InChI=1S/C25H33ClO6/c1-5-21(31)32-25(20(30)13-27)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,26)19(29)12-23(18,25)4/h8-9,11,14,17-19,27,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H33ClO6
Molecular Weight 464.979
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

1976
91
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.419 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12107606/
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.985 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12107606/
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12107606/
100 μg 4 times / day multiple, respiratory
dose: 100 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
BECLOMETHASONE 17-MONOPROPIONATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Disc. AE: Epistaxis, Increased intraocular pressure...
AEs leading to
discontinuation/dose reduction:
Epistaxis (5 patients)
Increased intraocular pressure (1 patient)
Colon cancer (2 patients)
Nasal septum ulceration (2 patients)
Nasal discomfort (2 patients)
Sinusitis (2 patients)
Nasal congestion (1 patient)
Headache (1 patient)
Nasal mucosal disorder (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Disc. AE: Sinusitis, Nasopharyngitis...
AEs leading to
discontinuation/dose reduction:
Sinusitis
Nasopharyngitis
Nasal congestion
Headache
Infection respiratory
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
AEs

AEs

AESignificanceDosePopulation
Headache 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Increased intraocular pressure 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal congestion 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal mucosal disorder 1 patient
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Colon cancer 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal discomfort 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal septum ulceration 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Sinusitis 2 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Epistaxis 5 patients
Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-74 years
n = 414
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-74 years
Sex: M+F
Population Size: 414
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Headache Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Infection respiratory Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasal congestion Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Nasopharyngitis Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Sinusitis Disc. AE
320 ug 1 times / day steady, intranasal
Recommended
Dose: 320 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
unhealthy, 12-82 years
n = 935
Health Status: unhealthy
Condition: allergic rhinitis
Age Group: 12-82 years
Sex: M+F
Population Size: 935
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf
Page: page 114
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B3-032489
http://www.3bsc.com/index/pro_info.php?id=53753
AHH Chemical co.,ltd
MT-27153
http://www.ahhchemical.com/product/MT-27153.html
Chem Scene
CS-0120927
http://www.chemscene.com/5534-18-9.html
Chemspace
CSSB00020661129
https://chem-space.com/CSSB00020661129
LGC Standards
LGCFOR0199.01
https://www.lgcstandards.com/US/en/p/LGCFOR0199.01
LGC Standards
MM0199.01-0025
https://www.lgcstandards.com/US/en/p/MM0199.01-0025
Lab Network
LN01274417
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01274417
MedChem Express
HY-136239
https://www.medchemexpress.com/beclomethasone-17-propionate.html
MolPort
MolPort-006-116-979
https://www.molport.com/shop/molecule-link/MolPort-006-116-979
Smolecule
S600542
https://www.smolecule.com/products/s600542
THE BioTek
bt-307443
https://www.thebiotek.com/product/others/bt-307443
eNovation Chemicals
D700538
https://www.enovationchem.com/ProductDetails.asp?ProductID=D700538
PubMed

PubMed

TitleDatePubMed
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids.
2006 Mar
Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts.
2010 Oct 1
Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway.
2011 Dec
Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.
2013
Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes.
2013 May
Patents

Patents

20020106401
2
JP2005097221A
8
JPS597117A
3
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:26:09 GMT 2023
Edited
by admin
on Fri Dec 15 16:26:09 GMT 2023
Record UNII
5BGA9FD55H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BECLOMETHASONE 17-MONOPROPIONATE
Common Name English
9-CHLORO-11.BETA.,21-DIHYDROXY-16.BETA.-METHYL-3,20-DIOXOPREGNA-1,4-DIEN-17-YL PROPANOATE
Common Name English
BECLOMETHASONE 17-PROPIONATE
Common Name English
BECLOMETHASONE-17-MONOPROPIONATE
Common Name English
BECLOMETHASONE DIPROPIONATE IMPURITY H [EP IMPURITY]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-CHLORO-11-HYDROXY-16-METHYL-17-(1-OXOPROPOXY)-
Systematic Name English
9-CHLORO-11B,17,21-TRIHYDROXY-16B-METHYLPREGNA-1,4-DIENE-3,20-DIONE 17-MONOPROPIONATE
Common Name English
17-BMP
Common Name English
BECLOMETHASONE DIPROPIONATE RELATED COMPOUND H [USP-RS]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1048543
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
MESH
C065857
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
ECHA (EC/EINECS)
226-888-1
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
FDA UNII
5BGA9FD55H
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
RXCUI
1546384
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY RxNorm
PUBCHEM
62965
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
CAS
5534-18-9
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID20203899
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
DRUG BANK
DB14221
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
DAILYMED
5BGA9FD55H
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
NCI_THESAURUS
C90950
Created by admin on Fri Dec 15 16:26:10 GMT 2023 , Edited by admin on Fri Dec 15 16:26:10 GMT 2023
PRIMARY
Related Record Type Details
Structure of BECLOMETHASONE DIPROPIONATE
PRODRUG -> METABOLITE ACTIVE
MAJOR
PLASMA
Related Record Type Details
Structure of BECLOMETHASONE DIPROPIONATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of BECLOMETHASONE 17-MONOPROPIONATE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966